Skip to main content

Multifunctional Nanoparticles for Targeting Cancer Therapy

Buy Article:

$105.00 plus tax (Refund Policy)

Chemotherapy drug Doxorubicin and MRI imaging agent Iron Oxide were encapsulated in dual functional nanoparticles which is compose of PEG-Foliate acid polymers. The particle size was about 45 nm with a mono-dispersion measured by zeta-sizer instrument. The contrast of images in liver was enhanced after injection Nanoparticles via rabbit ear vein. PEG-FA coated Iron Oxide nanoparticles can selectively target to tumor site and effectively inhibit tumor growth which is subcutaneously bearing A2780 Overran cancer cells. It is feasible for cancer treatment with MRI imaging and chemotherapy simultaneously in vivo by injection dual functional nanoparticles.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: CANCER THERAPY; DOXORUBICIN; IRON OXIDE; MRI IMAGING; PEG-FA

Document Type: Research Article

Publication date: 2010-11-01

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more